DGAP-News: MorphoSys AG / Key word(s): Regulatory Approval Planegg/Munich, Germany, November 23, 2017 MorphoSys Announces That Its Licensee Janssen Has Received Approval for Tremfya(R) (Guselkumab) in Europe for the Treatment of Moderate-to-Severe Plaque Psoriasis
Tremfya(R) (guselkumab) is a fully human anti-IL-23 monoclonal antibody developed by Janssen and was generated utilizing MorphoSys's proprietary HuCAL antibody library technology. MorphoSys is eligible to receive royalties on net sales of Tremfya(R). Dr. Simon Moroney, Chief Executive Officer of MorphoSys AG, said: "We are very pleased that Janssen has now received market authorization for Tremfya(R) in Europe after U.S. approval was granted in July of this year. We expect this drug will provide an important treatment option for patients living with moderate-to-severe plaque psoriasis." "Guselkumab is the first antibody that has received approval in Europe based on MorphoSys's technologies. With more than 100 MorphoSys compounds currently in development, we look forward to advancing novel antibodies in a wide variety of serious diseases where we see a strong need for alternative treatment options", added Dr. Markus Enzelberger, Chief Scientific Officer of MorphoSys. Beyond plaque psoriasis, Janssen is studying Tremfya(R) (guselkumab) in a Phase 3 psoriatic arthritis development program. Further information can be found in the press release issued by Janssen on November 23, 2017. About Psoriasis
HuCAL(R), HuCAL GOLD(R), HuCAL PLATINUM(R), CysDisplay(R), RapMAT(R), arYla(R), Ylanthia(R), 100 billion high potentials(R), Slonomics(R), Lanthio Pharma(R) and LanthioPep(R) are registered trademarks of the MorphoSys Group. Tremfya(R) is a registered trademark of Janssen Biotech, Inc. This communication contains certain forward-looking statements concerning the MorphoSys group of companies. The forward-looking statements contained herein represent the judgment of MorphoSys as of the date of this release and involve risks and uncertainties. Should actual conditions differ from the Company's assumptions, actual results and actions may differ from those anticipated. MorphoSys does not intend to update any of these forward-looking statements as far as the wording of the relevant press release is concerned. For more information, please contact: MorphoSys AG Jochen Orlowski Alexandra Goller Tel: +49 (0) 89 / 899 27-404 Additional features: Document: http://n.eqs.com/c/fncls.ssp?u=XFFLUTVUGC Document title: Media Release 23.11.2017 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. |
Language: | English |
Company: | MorphoSys AG |
Semmelweisstr. 7 | |
82152 Planegg | |
Germany | |
Phone: | +49 (0)89 899 27-0 |
Fax: | +49 (0)89 899 27-222 |
E-mail: | investors@morphosys.com |
Internet: | www.morphosys.com |
ISIN: | DE0006632003 |
WKN: | 663200 |
Indices: | TecDAX |
Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange |
End of News | DGAP News Service |